Clinical Trial Update: Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluated the efficacy and safety of GLYX-13 in adults with major depressive disorder who had an inadequate response to antidepressants; the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• GLYX-13 (Rapastinel)

Snippet

Sponsor: Naurex, Inc, an affiliate of Allergan plc | Conditions: Major Depressive Disorder | Phase 2 | Status: COMPLETED